Zoetis Inc., ZTS is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Zoetis Inc., ZTS has a market cap of 24913.72. Since its IPO date on the 2/1/2013, Zoetis Inc., ZTS performance year to date is 6.16%. Today Zoetis Inc., ZTS has gained 0.04%, with a current price of 50.47.
Ownership of the company is 0.01% for insider ownership while institutional ownership is 94.80%. The management of the company have seen the company have a payout ratio of 26.50%. Return of assets are at 9.00%, with return on investment at 5.70%.
In terms of debt levels and profit levels, Zoetis Inc., ZTS is seeing a long-term debt/equity of 2.82. While Total debt/equity is 2.82. With a profit margin of 14.10%, this is combined with a gross margin of 65.30%, and operating margin of 21.80%. Zoetis Inc. ability to meet debt levels, with a current ratio of 3.2, while the quick ratio is 1.7.
For the last year Zoetis Inc., ZTS has seen a EPS growth of -41.90%. A performance for the year of 8.94%. The 52-week high is -4.84%, and the 52-week low is 32.73%. The average volume for Zoetis Inc., ZTS is 408345.
With a target price of 55.85, can Zoetis Inc., ZTS reach this target? Looking at the value indicators of Zoetis Inc., ZTS. Zoetis Inc. has a P/E of 36.53 and a forward P/E of 21.55. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.86. Zoetis Inc. also has a P/S and a P/B of 5.1 and 15.77 respectively. For P/cash, Zoetis Inc. has a value of 38.27, while it is 48.38 for P/free cash flow.
At the current price of 50.47, Zoetis Inc. has a dividend yield of 0.75%. We see a return on equity of 53.30%.
Looking more long-term Zoetis Inc., is projected to get an EPS growth for the next five years of 12.77%. In the short-term an EPS growth of 20.48% in the next year is forecasted. This is after a EPS growth of -41.90% for this year and for the last five years a 25.10% growth has been seen.